Skip to main content


Buy Article:

$39.50 plus tax (Refund Policy)


The use of chronic systemic corticosteroids in allergic diseases should be restricted to cases where these agents are essential. Potentially fatal asthma and idiopathic anaphylaxis are examples of essential need for prednisone. The usual dose requirements on an alternate day regimen are often modest in these diseases, and complications of steroid therapy are minimal and are of no major concern particularly when the alternative may be a fatality. In spite of these facts, certain patients have a phobic response to the requirement for prednisone therapy. We report seven cases of prednisonephobia and classify this phobia as interpersonal, iatrogenic, bibliophilic, or parental. Some of these phobic reactions may seriously interfere with medical management or patient survival. An information sheet is included which may help certain of these patients.

Document Type: Research Article


Publication date: November 1, 1989

More about this publication?
  • Allergy and Asthma Proceedings is a peer reviewed publication dedicated to distributing timely scientific research regarding advancements in the knowledge and practice of allergy, asthma and immunology. Its primary readership consists of allergists and pulmonologists.

    The goal of the Proceedings is to publish articles with a predominantly clinical focus which directly impact quality of care for patients with allergic disease and asthma.

    Featured topics include asthma, rhinitis, sinusitis, food allergies, allergic skin diseases, diagnostic techniques, allergens, and treatment modalities. Published material includes peer-reviewed original research, clinical trials and review articles.

    Articles marked "F" offer free full text for personal noncommercial use only.

    The journal is indexed in Thomson Reuters Web of Science and Science Citation Index Expanded, plus the National Library of Medicine's PubMed service.
  • Editorial Board
  • Information for Authors
  • Submit a Paper
  • Information for Advertisers
  • Reprint Requests
  • Ingenta Connect is not responsible for the content or availability of external websites

Access Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Partial Open Access Content
Partial Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more